Crow Point Partners’s Myriad Genetics MYGN Stock Holding History

Crow Point Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-6,941	Closed	-$230K	–	128
2019 Q1	$230K	Buy	+6,941	New	+$211K	0.04%	102
2018 Q4	–	Sell	-6,098	Closed	-$281K	–	148
2018 Q3	$281K	Buy	6,098 +467	+8%	+$20.8K	0.05%	119
2018 Q2	$209K	Buy	5,631 +4,610	+452%	+$156K	0.04%	110
2018 Q1	$30K	Buy	+1,021	New	+$34.5K	0.01%	226

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Crow Point Partners's MYGN Position: Q2 2019 in Review

Crow Point Partners sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 6,941 shares — an estimated $230K sold.

Crow Point Partners first reported a position in MYGN in Q1 2018 and held it in 4 quarters. The position peaked at $281K in Q3 2018. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

Crow Point Partners reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
Crow Point Partners sold 6,941 Myriad Genetics shares in Q2 2019, an estimated $230K.
Crow Point Partners first reported a position in Myriad Genetics in Q1 2018 and held it in 4 quarters.
Crow Point Partners's Myriad Genetics position peaked at $281K in Q3 2018.
235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Crow Point Partners's 13F filing for Q2 2019, filed 14 Aug 2019.